@article{bdcd335b9f1e457cb94fd091f63983a6,
title = "Combination Therapies for Advanced Hepatocellular Carcinoma: Biomarkers and Unmet Needs",
abstract = "The novel combination of checkpoint inhibitors targeting the PD(L)1 pathway and anti-VEGFA therapy has revolutionized the treatment landscape of advanced hepatocellular carcinoma (HCC). However, biomarkers predictive of response to these therapies are still lacking, representing a major clinical challenge.",
author = "Sarah Cappuyns and Llovet, {Josep M.}",
note = "Funding Information: J.M. Llovet reports grants and personal fees from Bayer HealthCare Pharmaceuticals, Eisai Inc., and Ipsen; grants from Boehringer-Ingelheim; and personal fees from Eli Lilly and Company, Merck, Bristol-Myers Squibb, Glycotest, Nucleix, Genentech, Roche, AstraZeneca, Omega Therapeutics, Iylon, Mina Alpha, and Boston Scientific outside the submitted work. No disclosures were reported by the other author. Funding Information: J.M. Llovet is supported by grants from Cancer Research UK, Fondazione AIRC and Fundaci{\'o}n Cient{\'i}fica de la Asociaci{\'o}n Espa{\~n}ola Contra el C{\'a}ncer (HUNTER, Ref. C9380/A26813), the Samuel Waxman Cancer Research Foundation, Generalitat de Catalunya (AGAUR, SGR-1358), and the Spanish National Health Institute (MICINN, PID2019-105378RB-I00). S. Cappuyns is supported by a strategic basic research fellowship from Research Foundation – Flanders (FWO). Publisher Copyright: {\textcopyright}2022 American Association for Cancer Research.",
year = "2022",
month = aug,
day = "15",
doi = "10.1158/1078-0432.CCR-22-1213",
language = "English",
volume = "28",
pages = "3405--3407",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "16",
}